Vista Pharmaceuticals
VISTAPHARMACEUTICALSLTD NSE
Vista Pharmaceuticals
HealthcareNSE: VISTAPHARMACEUTICALSLTD BSE: 524711 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹35.12 Cr
Volatility
Moderate
P/E Ratio
-2.9
EBITDA
₹-14.62 Cr
Return on Equity
-10.23%
Debt to Equity
0.28
Book Value
₹5.92
EPS
₹0
52W High
₹10.75
52W Low
₹5.5
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Stock is trading at 0.97 times its book value
- Debtor days have improved from 347 to 21.6 days.
Weaknesses
4- Company has low interest coverage ratio.
- Promoter holding is low: 21.2%
- Company has a low return on equity of -17.1% over last 3 years.
- Promoter holding has decreased over last 3 years: -9.29%
Growth Rate
Revenue Growth
-48.57% lower than
3Y
Net Income Growth
251% lower than
3Y
Cash Flow Change
-42.16% higher than
3Y
ROE
-8.25% higher than
3Y
ROCE
-0.77% higher than
3Y
EBITDA Margin (Avg.)
649% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.98 | 3.47 | 1.7 | 3.13 | 1.8 | 2.49 | 2.56 | 3.23 | 1.52 | 1.46 | 2.42 | 0 | 0 |
| Expenses | 2.9 | 4.64 | 3.44 | 2.87 | 2.58 | 3.32 | 4.08 | 4.14 | 2.63 | 4.89 | 5.42 | 7.06 | 0.84 |
| Operating Profit | -0.92 | -1.17 | -1.74 | 0.26 | -0.78 | -0.83 | -1.52 | -0.91 | -1.11 | -3.43 | -3 | -7.06 | -0.84 |
| OPM % | -46.46% | -33.72% | -102.35% | 8.31% | -43.33% | -33.33% | -59.38% | -28.17% | -73.03% | -234.93% | -123.97% | — | — |
| Other Income | 0.13 | 0.08 | 0.02 | 0.1 | 0.07 | 0.01 | 0.12 | 0.24 | 0 | 0.19 | 0.09 | 0.03 | 0.04 |
| Interest | 0.33 | 0.32 | 0.3 | 0.28 | 0.28 | 0.25 | 0.22 | 0.21 | 0.19 | 0.18 | 0.18 | 0.55 | 0.34 |
| Depreciation | 0.17 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.19 | 0.18 | 0.18 | 0.2 | 0.19 | 0.19 | 0.19 |
| PBT | -1.29 | -1.59 | -2.2 | -0.1 | -1.17 | -1.25 | -1.81 | -1.06 | -1.48 | -3.62 | -3.28 | -7.77 | -1.33 |
| Tax % | -25.58% | 27.04% | -25.91% | -190% | -26.5% | -22.4% | -26.52% | 40.57% | -12.84% | -28.45% | -29.27% | -24.58% | -25.56% |
| Net Profit | -0.95 | -2.02 | -1.63 | 0.09 | -0.86 | -0.97 | -1.32 | -1.5 | -1.29 | -2.59 | -2.32 | -5.86 | -0.99 |
| EPS in Rs | -0.26 | -0.55 | -0.44 | 0.02 | -0.23 | -0.26 | -0.36 | -0.41 | -0.21 | -0.42 | -0.38 | -0.95 | -0.16 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 15 | 24 | 29 | 31 | 23 | 1 | 0 | 1 | 10 | 10 | 5 | 4 |
| Expenses | 11 | 13 | 21 | 24 | 30 | 28 | 3 | 2 | 5 | 13 | 14 | 20 | 18 |
| Operating Profit | 3 | 3 | 3 | 5 | 1 | -5 | -2 | -1 | -4 | -3 | -4 | -15 | -14 |
| OPM % | 20% | 17% | 13% | 18% | 4% | -21% | -136% | -326% | -432% | -33% | -41% | -271% | -369% |
| Other Income | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 1 | 1 | 1 | 3 | 1 | -4 | -4 | -3 | -6 | -5 | -5 | -16 | -16 |
| Tax % | -9% | 8% | -2% | 23% | 18% | -7% | -47% | -66% | -4% | -13% | -12% | -25% | — |
| Net Profit | 1 | 1 | 1 | 2 | 1 | -4 | -2 | -1 | -6 | -5 | -5 | -12 | -12 |
| EPS in Rs | 0.11 | 0.06 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.23 | -1.26 | -1.96 | -1.91 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 12 | 12 |
| Reserves | 5 | 6 | 11 | 26 | 30 | 24 | 25 | 28 | 29 | 31 | 33 | 24 |
| Borrowings | 4 | 8 | 11 | 11 | 11 | 15 | 11 | 13 | 10 | 8 | 7 | 10 |
| Other Liabilities | 8 | 7 | 14 | 10 | 6 | 6 | 9 | 8 | 9 | 10 | 7 | 9 |
| Total Liabilities | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
| Fixed Assets | 11 | 10 | 13 | 18 | 21 | 21 | 20 | 19 | 20 | 19 | 19 | 18 |
| CWIP | 0 | 0 | 2 | 7 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 12 | 16 | 26 | 28 | 24 | 22 | 24 | 27 | 27 | 29 | 31 | 26 |
| Total Assets | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -4 | -2 | 3 | -5 | 3 | 1 | -7 | -1 | -2 | -5 | -7 | -4 |
| Investing | 0 | 0 | -4 | -11 | -6 | -2 | 0 | 0 | -1 | -1 | 0 | -1 |
| Financing | 4 | 3 | 6 | 11 | 1 | 0 | 7 | 1 | 3 | 6 | 8 | 5 |
| Net Cash Flow | 0 | 0 | 5 | -4 | -1 | -1 | 0 | 0 | 0 | 0 | 1 | -1 |
| Free Cash Flow | -4 | -3 | -1 | -15 | -2 | -1 | -7 | -1 | -3 | -6 | -7 | -5 |
| CFO/OP | -131 | -89 | 84 | -86 | 299 | -17 | 390 | 78 | 64 | 149 | 163 | 30 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 300 | 231 | 136 | 137 | 98 | 165 | 624 | 9,789 | 4,106 | 515 | 505 | 22 |
| Inventory Days | 10 | 97 | 185 | 250 | 162 | 148 | 4,840 | 9,204 | 991 | 279 | 359 | 770 |
| Days Payable | 359 | 236 | 293 | 209 | 76 | 79 | 2,555 | 5,297 | 1,007 | 304 | 244 | 443 |
| Cash Conversion Cycle | -50 | 92 | 27 | 178 | 184 | 234 | 2,909 | 13,696 | 4,089 | 490 | 620 | 349 |
| Working Capital Days | -8 | 206 | 12 | 137 | 137 | 81 | 1,681 | 10,154 | 3,460 | 318 | 440 | -95 |
| ROCE % | 14% | 10% | 9% | 12% | 6% | -5% | -5% | -4% | -10% | -8% | -9% | -30% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vista Pharmaceuticals insights
61 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
12 Sep - Mrs. Barkha Jain resigned as Company Secretary and Compliance Officer effective 4 September 2026. 12 Sep - Mrs. Barkha Jain resigned as Company Secretary and Compliance Officer effective 4 September 2026.
2
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil. 29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil.
3
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil. 29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil.
5
Closure of Trading Window
27 Mar - Vista Pharmaceuticals: trading window closed from 1 April 2026 until 48 hours after audited results for year/quarter ending 31.03.2026. 27 Mar - Vista Pharmaceuticals: trading window closed from 1 April 2026 until 48 hours after audited results for year/quarter ending 31.03.2026.
2
Board Meeting Intimation for Approval Of Un Audited Financials Results For The Quarter Ended 30.06.2026 13 Aug 2026
Intimation
Frequently Asked Questions about Vista Pharmaceuticals
What does Vista Pharmaceuticals Ltd do?
Incorporated in 1992, Vista Pharmaceuticals
Ltd manufactures and sells pharmaceutical, medical and veterinary preparations[1]
Where is Vista Pharmaceuticals Ltd (524711) listed?
Vista Pharmaceuticals Ltd trades as VISTAPHARMACEUTICALSLTD on the NSE and under code 524711 on the BSE.
Which sector does Vista Pharmaceuticals Ltd belong to?
Vista Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has a market capitalisation of ₹35.12 Cr, which places it in the Small Cap band.
What is the PE ratio of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd trades at a PE ratio of -2.90, on earnings per share of ₹0, against a book value of ₹5.92 per share.
What is the 52-week high and low of Vista Pharmaceuticals Ltd?
Over the last 52 weeks Vista Pharmaceuticals Ltd has traded between ₹5.5 and ₹10.75.
What is the Return on Equity (ROE) of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd reported a return on equity of -10.23%. Its debt-to-equity ratio is 0.28.
Company Information
Incorporated in 1992, Vista Pharmaceuticals Ltd manufactures and sells pharmaceutical, medical and veterinary preparations[1]
Website vistapharmaceuticals.com
Face Value ₹ 2
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524711.md for Vista Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.